GSK,SNY,TEVA -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters4 hours ago

    Teva's Yitzhak Peterburg resigns from board

    Teva Pharmaceuticals Industries Ltd said on Tuesday Yitzhak Peterburg, who previously served as the company's chairman and interim chief executive, resigned from its board, effective immediately. The debt-laden ...

  • TheStreet.com7 hours ago

    Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi

    French drug-maker Sanofi contends its Dengue vaccine is good for the country. After 730,000 children were vaccinated, the Philippine government stopped the program on data the drug-maker released that ...

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacks8 hours ago

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • Market Realist10 hours ago

    Spectrum Pharmaceuticals’ Product Licensing Agreements

    In 2012, Spectrum Pharmaceuticals (SPPI) acquired the rights to market Zevalin outside the US from Bayer for 19 million euros.

  • Teva’s Working With Evercore to Review Debt Options
    Bloomberg10 hours ago

    Teva’s Working With Evercore to Review Debt Options

    Teva Pharmaceutical Industries Ltd.’s new Chief Executive Officer Kare Schultz is working with advisory firm Evercore Inc. to review options for the beleaguered drugmaker’s outstanding debt, according ...

  • Reuters10 hours ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters10 hours ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reutersyesterday

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • TheStreet.comyesterday

    Teva Stock Rises After Announcing Launch of Generic Viagra Competitor

    Viagra has annual sales of about $1.4 billion.

  • Reutersyesterday

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • Sex, Drugs, and Teva Pharmaceutical Industries (TEVA)
    SmarterAnalystyesterday

    Sex, Drugs, and Teva Pharmaceutical Industries (TEVA)

    Today, the generic drug giant announced the exclusive launch of its generic Viagra (sildenafil citrate) tablets in the U.S. Viagra (generic name sildenafil) is a drug used in the treatment of erectile dysfunction, also known as impotence. Introduced by Pfizer Inc. in March 1998, Viagra has generated about $1.4 billion in the U.S., according to IMS data as of August 2017.

  • Monday’s Vital Data: Facebook Inc (FB), Monsanto Company (MON) and Teva Pharmaceutical Industries Limited (TEVA)
    InvestorPlaceyesterday

    Monday’s Vital Data: Facebook Inc (FB), Monsanto Company (MON) and Teva Pharmaceutical Industries Limited (TEVA)

    U.S. stock futures are trading broadly higher this morning, putting the major market indices on track for fresh all-time highs. Wall Street is showing little fear ahead of Wednesday’s Federal Reserve meeting, when the central bank is expected to hike interest rates for the third and final time of 2017.  Furthermore, the European Central Bank and the Bank of England are also scheduled to make policy announcements this week. Heading into the open, Dow Jones Industrial Average futures have gained 0.16%, S&P 500 futures have added 0.06% and Nasdaq-100 futures have rallied 0.09%.

  • 2018 is setting up like 2006—a boom year 2 years before the financial crisis
    Yahoo Finance Videoyesterday

    2018 is setting up like 2006—a boom year 2 years before the financial crisis

    Yahoo Finance's Alexis Christoforous and Jared Blikre discuss the current market action.

  • Teva Pharma continues to lead the IQ100
    CNBC Videosyesterday

    Teva Pharma continues to lead the IQ100

    The CNBC IQ100 index beating the broader market over one year up over 19%. Today's leaders include Teva Pharma, Cardinal Health and Mattel. The laggards Sony, Kimberly-Clark and Clorox.